Mr Stephen Gamble

Stephen Gamble

University position

Research Assistant

Institutes

Wellcome Trust Sanger Institute

Research Theme

Cellular and Molecular Neuroscience

Interests

Currently working in molecular biology in the Cancer, Ageing and Somatic Mutation (CASM) programme at the Sanger Institute. My previous research experience has including work in the biological basis of mental illness using neurobiology, biochemistry and computing.

My current work is not primarily neurobiology based, only occasionaly working with neurological material and cell lines. My work programme is determined by requests from more senior scientists.

Outside this I follow my own areas of interest. Most recently I have been interested in the roles of mitochondria and autoimmunity in neurological disease, and the involvement of similar genes found in cancers in these diseases. As an example, why do people that have autoimmune diseases like coeliac disease have increased risk of both colon cancer and dementia?

I am interested in prion diseases, biological basis of dementias and schizophrenia and the analysis of sequential behaviour.

Research Focus

Keywords

genetics

molecular biology

Clinical conditions

No direct clinical relevance

Equipment

Cell culture

Collaborators

No collaborators listed

Associated News Items


    Publications

    1989

    Annett LE, Ridley RM, Gamble SJ, Baker HF (1989), “Social withdrawal following amphetamine administration to marmosets.” Psychopharmacology (Berl) 99(2):222-9 Details

    1985

    Taylor GR, Crow TJ, Carter GI, Gamble SJ (1985), “Cytopathogenic cerebrospinal fluid from neurological and psychiatric patients.” Exp Mol Pathol 42(2):271-7 Details

    Taylor GR, Roberts GW, Crow TJ, Royds JA, Gamble SJ, Taylor CB, Carter GI, Timperley WR (1985), “The cytopathogenic agent in CSF: evidence for a relationship with enolase levels.” J Neurol Neurosurg Psychiatry 48(3):281 Details

    1983

    Annett LE, Ridley RM, Gamble SJ, Baker HF (1983), “Behavioural effects of intracerebral amphetamine in the marmoset.” Psychopharmacology (Berl) 81(1):18-23 Details

    Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, Gamble SJ (1983), “Adverse effects of anticholinergic medication on positive schizophrenic symptoms.” Psychol Med 13(3):513-27 Details

    Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983), “Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.” Science 220(4596):530-2 Details

    Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983), “Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.” Adv Biochem Psychopharmacol 37:299-308 Details

    1981

    Waddington JL, Gamble SJ (1981), “Prolonged dopamine receptor blockade in rats after termination of long-term depot fluphenazine.” Lancet 1(8234):1375-6 Details

    Waddington JL, Gamble SJ, Bourne RC (1981), “Sequelae of 6 months continuous administration of cis(Z)-and trans(E)-flupenthixol in the rat.” Eur J Pharmacol 69(4):511-3 Details

    1980

    Owen F, Cross AJ, Waddington JL, Poulter M, Gamble SJ, Crow TJ (1980), “Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration.” Life Sci 26(1):55-9 Details

    Waddington JL, Gamble SJ (1980), “Emergence of apomorphine-induced 'vacuous chewing' during 6 months continuous treatment with fluphenazine decanoate.” Eur J Pharmacol 68(3):387-8 Details

    Waddington JL, Gamble SJ (1980), “Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.” Eur J Pharmacol 67(4):363-9 Details

    Waddington JL, Gamble SJ (1980), “Differential effects of ageing on distinct features of apomorphine stereotypy in the adult rat.” Neurosci Lett 20(1):95-9 Details

    Waddington JL, Gamble SJ (1980), “Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3 1/2 months continuous administration of haloperidol: some methodological issues.” Psychopharmacology (Berl) 71(1):75-7 Details